Microbubble-Enhanced Clotbust Treatment of Acute Ischemic Stroke

This study has been terminated.
(for administrative reasons)
Information provided by:
ImaRx Therapeutics
ClinicalTrials.gov Identifier:
First received: July 25, 2007
Last updated: NA
Last verified: July 2007
History: No changes posted

The study is designed to examine the safety, tolerability, and activity of a combination of microbubbles (perflutren lipid microsphere [Definity®]) and continuous monitoring with 2 MHz transcranial Doppler ultrasound (TCD) as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.

Condition Intervention Phase
Acute Ischemic Stroke
Drug: perflutren lipid microsphere
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Microbubble-Enhanced Clotbust Treatment of Acute Ischemic Stroke

Resource links provided by NLM:

Further study details as provided by ImaRx Therapeutics:

Primary Outcome Measures:
  • Incidence of symptomatic intracranial hemorrhage [ Time Frame: 72 hours ]

Secondary Outcome Measures:
  • Complete recanalization of the occluded artery (TIBI 4-5) [ Time Frame: End of treatment ]
  • NIHSS score of 0-2 [ Time Frame: 24 hours ]
  • Favorable outcome (modified Rankin Scale or NIHSS 0-1) [ Time Frame: 3 months ]

Study Start Date: March 2005
Study Completion Date: May 2006
Intervention Details:
    Drug: perflutren lipid microsphere
    Other Name: Definity

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Measurable focal neurological deficit (National Institutes of Health Stroke Scale [NIHSS] score > 4 points)
  • tPA eligible
  • Occlusion of the middle cerebral artery

Exclusion Criteria:

  • Right to left cardiac shunt
  • Uncontrolled hypertension
  • Absent temporal windows
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00507806

Sponsors and Collaborators
ImaRx Therapeutics
Principal Investigator: Andrei Alexandrov, MD The University of Texas Health Science Center, Houston
  More Information

ClinicalTrials.gov Identifier: NCT00507806     History of Changes
Other Study ID Numbers: MRX-815-401
Study First Received: July 25, 2007
Last Updated: July 25, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by ImaRx Therapeutics:
Acute Ischemic Stroke
Transcranial Doppler ultrasound
Symptomatic Intracranial Hemorrhage
modified Rankin Scale

Additional relevant MeSH terms:
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Nervous System Diseases
Pathologic Processes
Vascular Diseases
Contrast Media
Diagnostic Uses of Chemicals
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 13, 2015